AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES NEW PRESIDENT KENNETH H. BURK, PH.D.
AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES NEW PRESIDENT KENNETH H. BURK, PH.D. NOTRE DAME, Ind., Oct. 19 /PRNewswire/ -- American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA) announced today that Kenneth H. Burk, Ph.D. has been appointed to the position of president, chief operating officer and a director of ABS. Dr. Burk will join ABS's international network from Genelabs Technologies, Inc. where his position was president of its subsidiary, BioTech Resources, Inc. (BTR). He has extensive experience as a scientist, leader and manager. In March 1991, he successfully negotiated a merger between BTR and Genelabs Technologies, Inc. Prior to joining BTR, Dr. Burk spent eight years with Warner Lambert. He was promoted from senior research scientist to director of research and development where he oversaw and participated in seven new product introductions and brought eight products to final development stage. Under his direction, nine products were FDA approved and released. Dr. Burk holds nine patent applications in his name. Mr. Alfred J. Roach, chairman and founder of ABS welcomed Dr. Burk's appointment to the team. "We are pleased to have someone of Dr. Burk's background, caliber and experience in bringing new products through the FDA and into commercial use. He brings to our company an extraordinarily wide range of scientific knowledge and leadership skills and is precisely the kind of executive we want and need to translate our scientific advances into commercial successes." Dr. Burk stated that "the opportunity to join the excellent staff of ABS and to work on its advanced fields of biotechnology are exciting and highly promising prospects. I look forward to being involved in the medical breakthroughs pioneered by ABS scientists and, through team effort, bringing them to commercial fruition." Dr. Burk's appointment comes at an exciting time for ABS, as a number of breakthrough products are in various stages of development. In the cardiovascular area, ABS has developed and received FDA approval on CADKIT, a proprietary and patented diagnostic which measure fibrinogen levels in blood plasma. An Investigational New Drug (IND) application has been filed with the FDA seeking approval to begin human clinical trials on the company's proprietary and patented imaging agent that detects clots in the heart and lungs. ABS presently has other research projects in various stages of development. Dr. Kenneth H. Burk is a graduate of Baylor University and Texas Tech University and earned his Ph.D. from the University of Texas Graduate School of Biomedical Sciences, Houston, Texas. American Biogenetic Sciences, Inc. is a biopharmaceutical company which conducts research at the University of Notre Dame, Ind., Trinity College, Dublin, Ireland and University College Galway, Ireland, to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease. These antibodies are produced from the company's proprietary germ-free and virtually antigen-free mouse colony. -0- 10/19/92 /CONTACT: Fran Giambanco, senior vice president of American Biogenetic Sciences, 516-789-2600, or Phil Fried of The Dilenschneider Group, 212-922-0900, for American Biogenetic Sciences/ (MABXA) CO: American Biogenetic, Inc. ST: Indiana IN: MTC SU: PER
TM -- NY002 -- 1404 10/19/92 09:31 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 19, 1992|
|Previous Article:||VAN DORN ANNOUNCES 1992 THIRD QUARTER AND NINE MONTHS RESULTS|
|Next Article:||HUMPHREY RECEIVES CONTRACT FROM LORAL AERONUTRONIC|